Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)

Phase 3CompletedNCT00634309

AstraZeneca597 enrolled

Overview

A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

597

Conditions

Congestive Heart Failure

Interventions

CandesartanDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female aged 18 or above * Congestive Heart Failure with symptoms for more than 4 weeks before starting study * Provision of informed consent Exclusion Criteria: * Current low blood pressure with symptoms * Liver disease considered significant by the study doctor * Pregnant or lactating females

Outcomes

Primary Outcomes

Cardiovascular mortality or hospitalisation due to congestive heart failure

Time frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

Secondary Outcomes

Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI

Time frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.